Macron strengthens the no-confidence vote, and the European Union signs a contract with Valneva ... Epidemic update

The “Macron effect” has struck again: Tuesday, 149,000 French have set an appointment for the booster Covid vaccine on Doctolip, announced Wednesday morning the main site for medical appointments in the country. Maintaining the health pass to this third dose, which became necessary due to the decrease in immunity observed after six months, is responsible for this new momentum. Reaches 60 million doses of vaccine against Covid-19 by 2023.

  • The third dose: Macron boosts appointments

Emmanuel Macron’s intervention, watched by nearly 21 million people, had an effect. Maintaining a health card provided, for those over 65 years of age, to achieve the third dose of the vaccine significantly speeds up the scheduling of appointments. About 100,000 of these khans were reserved between 8:00 p.m. and 9:00 p.m., either during or immediately after his speech.

Some even predicted that, with Doctolib already recording 96,000 reminder appointments on Monday, versus about 50,000 daily (excluding weekends) on average in previous weeks. On the other hand, the effect was much weaker on the first doses, with barely 20,000 appointments on Tuesday, versus about 15,000 daily bookings previously.

The rush for appointments to Doctolib begins, after the speech of Emmanuel Macron.

The rush for appointments to Doctolib begins, after the speech of Emmanuel Macron.

Doctolip

limited offer. 2 months for 1 euro without commitment

  • Vaccines: the European Union signs with Valneva

The French-Austrian laboratory Valneva and the European Commission announced on Wednesday that they have reached an agreement on up to 60 million doses of a vaccine against Covid-19 by 2023. The contract stipulates that all member states can purchase approximately 27 million doses of the vaccine in 2022. , says the committee, with an additional 33 million doses in 2023.

See also  ▷ POL-KA: (PF) Pforzheim-Eutingen- Police use of animals

Valneva said in a press release that the agreement with the European Union must be concluded “after a final examination, in particular, of the quantities required by each of the member states of the European Union.”

That’s good news for the company, which was shaken in September when the British government terminated a contract for 100 million doses, and then its only order. In terms of timing, delivery of the vaccine to the European Union is scheduled for April 2022, subject to approval by European authorities.

  • Germany: Pfizer for people under the age of 30

The German Vaccination Committee (STIKO) on Wednesday recommended that those under 30 be vaccinated with the only vaccine from Pfizer-BioNTech, which risks developing myocarditis for this population due to Moderna. This recommendation also applies to pregnant women.

In France, after the results of a large study conducted by Epi-Phare were published, the High Health Authority of France (HAS) also advised against the use of the Moderna vaccine for those under 30 years of age.

  • Case explosion in Belgium

With an average of 8,000 new infections per day, Belgium is returning to a virus prevalence rate unreached for a year. Hospitalization follows the same trend: There are 2,000 Covid patients in Belgian hospitals, a level not seen in the country since May. Therefore, the Belgian authorities are again strongly encouraging remote work and the wearing of masks in all public places.

  • The World Health Organization is anxiously awaiting the second generation of vaccines

World Health Organization chief scientist Soumya Swaminathan said Tuesday that she is looking into the second generation of COVID-19 vaccines, which could include nasal sprays or birth control pills. She said on WHO social media channels that these second generation vaccines will have the advantage of being easier to use than needles and can be self-administered.

See also  Global COVID-19 eradication more feasible than polio: Study

At least 129 vaccines are being investigated, some of which are in clinical trials, and thus have been tested in humans, compared to 194 vaccines that have not yet reached this advanced stage. “It covers a whole range of technologies,” she said.

L’Express app

To continue analysis and decoding wherever you are

Download the app

Download the app

“It is still being studied but I am confident that some will be very safe and effective, and some will not,” she added. The World Health Organization will choose the most suitable and also consider using some of them to develop vaccines against other diseases.


opinions

chronic

Christoph Donner, writer.Christoph Donner

chronic

Economist and essayist, Nicolas Pozzo is the founder and director of Asterès Consulting.Nicolas Pozzo

chronic

ebony shalmani

chronic

Chronicle Donner.Christoph Donner

LEAVE A REPLY

Please enter your comment!
Please enter your name here